Thicker Lashes, Fatter Wallets

Recs

4

Motley Fool Stock Advisor

Since 2002, David and Tom Gardner have returned 29.35% while the S&P 500 returned -11.11%. Try Stock Advisor free for 30 days.

Stock Advisor

Watch out Bare Escentuals (Nasdaq: BARE) and Estee Lauder (NYSE: EL), there's a new kid on the market trying to smear your mascara.

On Friday, the Food and Drug Administration approved Allergan's (NYSE: AGN) Latisse, a treatment for hypotrichosis of eyelashes -- that means sparse eyelashes, for those not vain enough to know.

Small eyelashes are far from a small market -- the global market is around $3.7 billion. But Allergan is going to have a hard time capturing much of that market in this economy, considering the drug will run $120 a month. You have to look no further than how poorly cosmetic-laser makers like Syneron Medical (Nasdaq: ELOS) and Palomar Medical (Nasdaq: PMTI) have been doing over the last couple of years to see that beauty treatments are among the first things to be cut when the paycheck is in jeopardy.

But this economy will eventually rebound and Allergan could ultimately hit its target of $500 million per year in sales once the vainness returns. By comparison, Allergan is expecting nearly $1.3 billion in sales from Botox this year.

Ironically, Latisse was originally designed to treat glaucoma and is sold under the brand name Lumigan, but the longer eyelashes were discovered as a side effect. It's not all that weird to have the same active ingredient sold under two brand names. For instance Pfizer's (NYSE: PFE) Viagra is also sold as Revatio, a treatment for pulmonary arterial hypertension (PAH). The different packaging probably costs the companies a little money, but it avoids sending doctors a mixed message from their sales reps about drugs doing four different things like Eli Lilly's (NYSE: LLY) antidepressant-turned-fibromyalgia-treatment Cymbalta.

Being dependent on discretionary spending, Allergan is likely to continue to tread water until the economy improves, but investors thinking about the long term don't really need to worry about their mascara running; they can ride the waves without crying.

Like this article? Get our best articles delivered direct to your inbox at no cost. Sign up for Foolwatch Weekly by entering your email below.

Syneron Medical is a selection of the Motley Fool Hidden Gems Pay Dirt and Rule Breakers services. Bare Escentuals is a recommendation of both Motley Fool Hidden Gems and Rule Breakers. Pfizer and Eli Lilly are Income Investor recommendations. Pfizer is also an Inside Value selection and the Fool owns shares. Try any of our Foolish newsletters today, free for 30 days

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 801468, ~/articles/ArticleHandler.aspx, 7/14/2009 2:47:37 PM

Keep Reading:

“Thicker Lashes, Fatter Wallets”

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

What Fools Are Saying

Get involved! »

Most Popular Articles

  1. The New Subprime7 days ago
  2. What the U.S. Needs: A New Tax System?6 days ago
  3. GM: This Stock Is Worthless3 days ago
Jul 14 at 2:46 PM

Market Summary

DJIA 8,348.53 +16.85 +0.20%
S&P 500 904.22 +3.17 +0.35%
NASD 1,799.34 +6.13 +0.34%
Sponsored by:

Related Tickers

Allergan, Inc.

CAPS Rating 5/5 Stars

$46.05

+0.15 (+0.33%)

Outperform327

Underperform18

Rate This Stock